genOway would like to thank Oxford Global for the quality of its Immuno Series 2023 conference. It was an excellent session with many networking opportunities in the biotech&pharma community, which allowed us to expand our activity in immuno-inflammation and immuno-oncology.

📧 Invitation to genOway booth at #AACR2023 in Orlando: Our team is ready to greet you at booth #3253 ! Find out how genOway’s preclinical models empowers #immuno-oncologists! To book a one-to-one meeting there: genoway.com/about/meet-us/…

We are now one week away from #AACR2023! #genOway's poster will explain how functional human myeloid cells in humanized BRGSF-HIS mice allow evaluation of myeloid-directed therapies. The poster presentation will take place April 18th. Join us there!

𝐑𝐞́𝐬𝐮𝐥𝐭𝐚𝐭𝐬 𝐚𝐧𝐧𝐮𝐞𝐥𝐬 𝟐𝟎𝟐𝟐 𝐫𝐞𝐜𝐨𝐫𝐝𝐬 ! ➿CA de 𝟏𝟕,𝟏 𝐌€, en croissance organique de +22%, ➿EBITDA de 𝟑,𝟐 𝐌€ en hausse de +119%, ➿Profitabilité record : 𝐦𝐚𝐫𝐠𝐞 𝐝’𝐄𝐁𝐈𝐓𝐃𝐀 𝐩𝐨𝐫𝐭𝐞́𝐞 𝐚̀ 𝟏𝟖,𝟖% ➿Cash-flow + 📢genoway.com/about/investor…

Join us at the 3rd Fc Receptor Pathway Targeted Therapies Summit in #Boston! 📌Save the date of April 18 to 20 and come meet us in person: genoway.com/about/meet-us/…

Want to know more about our 𝐇𝐒𝐀/𝐅𝐜𝐑𝐧 𝐦𝐨𝐝𝐞𝐥? 🔬Come and meet us at the @𝟑𝐫𝐝 𝐅𝐜 𝐑𝐞𝐜𝐞𝐩𝐭𝐨𝐫 𝐏𝐚𝐭𝐡𝐰𝐚𝐲 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝟐𝟎𝟐𝟑 👥👥 genoway.com/science-techno…

Only two days left before the opening of 𝐭𝐡𝐞 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐬𝐩𝐚𝐜𝐞 𝐚𝐭 𝐭𝐡𝐞 𝐀𝐀𝐂𝐑 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞! 🎊 Come at 𝐁𝐎𝐎𝐓𝐇 𝟑𝟐𝟓𝟑 𝐟𝐫𝐨𝐦 𝐀𝐩𝐫𝐢𝐥 𝟏𝟔 𝐭𝐨 𝟏𝟗 and learn more about our wide range of humanized preclinical models! aacr23.mapyourshow.com/8_0/exhview/in…

Good morning 𝐀𝐀𝐂𝐑 𝟐𝟎𝟐𝟑! Join us at 𝐩𝐨𝐬𝐭𝐞𝐫 𝐬𝐞𝐬𝐬𝐢𝐨𝐧 𝟐𝟓, in front of 𝐩𝐨𝐬𝐭𝐞𝐫 𝐧𝐮𝐦𝐛𝐞𝐫 𝟒𝟏𝟑𝟗 to discover how durable free myeloid cell transplantation is in 𝐁𝐑𝐆𝐒𝐅-𝐇𝐈𝐒 mouse model!

𝐀𝐀𝐂𝐑 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 in Orlando We look forward to seeing you at 𝐛𝐨𝐨𝐭𝐡 𝟑𝟐𝟓𝟑! Let's discuss your projects and see how our high-value preclinical mouse and cell models could help you accelerate your research! 🌠 aacr23.mapyourshow.com/8_0/floorplan/…

𝐊𝐚𝐝𝐞𝐫 𝐓𝐡𝐢𝐚𝐦, Sr VP, will present at the 𝟓𝐭𝐡 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐞𝐥𝐥 𝐄𝐧𝐠𝐚𝐠𝐞𝐫 𝐒𝐮𝐦𝐦𝐢𝐭 on April 26 at 1:30 pm. Want to learn more about the most appropriate preclinical model for evaluating the efficacy and irAE of T-cell activators? 📨genoway.com/about/meet-us/…

🎉Congratulations to @Senseibio for bringing 𝐒𝐍𝐒-𝟏𝟎𝟏 into the 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐡𝐚𝐬𝐞! We are proud to have been able to accompany the team in its preclinical studies with our our humanized mouse models 𝐁𝐑𝐆𝐒𝐅-𝐇𝐈𝐒 and 𝐊𝐈-𝐡𝐕𝐈𝐒𝐓𝐀. genoway.com/catalog/humani…

Yesterday, Kader THIAM gave a talk titled 'Challenging the predictability of Preclinical models for assessment of cell engagers' at the 5th Annual Cell Engager Summit in Boston. To know more about CD3 mouse model: genoway.com/catalog/immune…

Envie d'en savoir plus sur la vocation et la mission de la société genOway ? Ou sur ses résultats financiers ? 🎥 Retrouvez l'interview d'Alexandre Fraichard, fondateur et DG de genOway sur Investisseur.tv investisseur.tv/video/genoway-…

🌠 🌠 🌠 Vous voulez en savoir plus sur les résultats 2022 de genOway ? Alors ne manquez pas l'interview 🎥 ci-dessous de Benjamin Bruneau, DAF par Jean-Pierre Vacher dans #BourseEtValeurs !

Tomorrow, 𝐊𝐚𝐝𝐞𝐫 𝐓𝐇𝐈𝐀𝐌, Sr VP, Discovery & Preclinical Models will present 🎙️at the STING & TLR-Targeting Therapies Summit 2023. His talk will review the assessment of STING and TLR targeting immune-targeting agents in preclinical models. 👉 genoway.com/about/meet-us/…

How to choose the most appropriate model to evaluate the efficacy and safety of STING-targeting agents? Kader THIAM highlighted the complementary approaches of our BRGSF-HIS and our KI hSTING at the 4th STING & TLR-Targeting Therapies Summit. 👉 genoway.com/catalog/humani…

Check out the insightful article published with Bioinsights on Assessing efficacy & MoA of mono & combo immunotherapies in preclinical humanized models (with Kader Thiam, Arjun Surya, Curadev & Edward van der Horst, Sensei Bio) 👉 lnkd.in/eutVbSQP

genOway dévoile Route 50+, son nouveau plan stratégique: ▪ 50 M€ de chiffre d’affaires visé à horizon 2028, exclusivement par croissance organique ▪ Stratégie de croissance externe pour accélérer davantage le développement ▪ Marge d’EBITDA minimum de 15% tout au long du plan

Our double humanized HSA/FcRn mouse model is a valuable tool for preclinical development of HSA and FcRn-oriented therapeutics in a variety of fields, such as oncology, infectious diseases, and autoimmune diseases 👉genoway.com/product/catalo…

🔬 In their Society for Immunotherapy of Cancer 2024 poster, AstraZeneca used our Pan hCD3 mouse model to assess the efficacy of their T-cell engager, AZD5863, in reshaping the TME and in inhibiting tumor growth in mono- or combotherapy, enabling it to move to clinical trials 👉 genoway.com/science/public…